Analyst rating accuracy & track record
Matthew Harrison is an equity research analyst at Morgan Stanley. Bullish Whales has scored 35 of their stock calls across 9 companies. Their picks beat their sector 45% of the time over the next 12 months, and their price targets were reached 46% of the time within a year.
Track record
Bullish Whales has scored 35 of Matthew Harrison's stock calls across 9 companies, dating back to 2017. Their rated stocks beat their own sector 45% of the time over the next 12 months. On a typical call, a Harrison pick returned −9.0% more than its sector over the following year.
Of the scored calls, 25 were bullish (Buy) and 10 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.
Coverage & ratings
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 TNYATenaya Therapeutics Inc | Buy | $5.00 | Mar 2025 | +27.0% | Miss |
 DNLIDenali Therapeutics Inc | Buy | $33.00 | Mar 2025 | +36.2% | Miss |
 ALECAlector Inc | Sell | $3.00 | Nov 2024 | +56.7% | Hit |
 PHVSPharvaris BV | Buy | $34.00 | Apr 2024 | −26.2% | Miss |
| PHVSPharvaris BV | Buy | $34.00 | Apr 2024 | −34.5% | Miss |
| PHVSPharvaris BV | Buy | $35.00 | Dec 2023 | −36.0% | Miss |
| PHVSPharvaris BV | Buy | $32.00 | Nov 2023 | +5.6% | Hit |
 ZNTLZentalis Pharmaceuticals Llc | Buy | $38.00 | Nov 2023 | −78.9% | Miss |
| PHVSPharvaris BV | Buy | $34.00 | Aug 2023 | −30.5% | Miss |
 INVAInnoviva Inc | Sell | $10.00 | Mar 2023 | −23.4% | Miss |
 ONCBeiGene, Ltd. | Buy | $321.00 | Feb 2023 | −41.3% | Miss |
| INVAInnoviva Inc | Sell | $13.00 | Jan 2023 | −26.0% | Hit |
 AVIRAtea Pharmaceuticals Inc | Sell | $4.00 | Jan 2023 | +25.6% | Hit |
 ADAGAdagene Inc | Buy | $5.00 | Jan 2023 | +99.7% | Miss |
| ONCBeiGene, Ltd. | Buy | $325.00 | Jan 2023 | −44.6% | Miss |
| INVAInnoviva Inc | Sell | $14.00 | Oct 2022 | +6.2% | Hit |
| ONCBeiGene, Ltd. | Buy | $295.00 | Oct 2022 | +7.9% | Miss |
| ADAGAdagene Inc | Buy | $7.00 | Sep 2022 | −11.7% | Miss |
| AVIRAtea Pharmaceuticals Inc | Sell | $7.00 | Aug 2022 | +64.1% | Hit |
| INVAInnoviva Inc | Sell | $13.00 | Aug 2022 | +9.4% | Hit |
| INVAInnoviva Inc | Sell | $12.00 | Jul 2022 | +18.6% | Hit |
| ONCBeiGene, Ltd. | Buy | $293.00 | Jul 2022 | +10.0% | Miss |
| INVAInnoviva Inc | Sell | $13.00 | Apr 2022 | +37.1% | Hit |
| ONCBeiGene, Ltd. | Buy | $338.00 | Apr 2022 | +38.1% | Miss |
| ADAGAdagene Inc | Buy | $15.00 | Feb 2022 | −76.4% | Miss |
| AVIRAtea Pharmaceuticals Inc | Sell | $7.00 | Jan 2022 | +41.0% | Hit |
| AVIRAtea Pharmaceuticals Inc | Buy | $37.00 | Aug 2021 | −71.0% | Hit |
| ONCBeiGene, Ltd. | Buy | $407.00 | Aug 2021 | −32.5% | Hit |
| ADAGAdagene Inc | Buy | $33.00 | Jul 2021 | −90.9% | Miss |
| AVIRAtea Pharmaceuticals Inc | Buy | $35.00 | Jun 2021 | −71.6% | Hit |
| ONCBeiGene, Ltd. | Buy | $409.00 | Jun 2021 | −67.7% | Hit |
| AVIRAtea Pharmaceuticals Inc | Buy | $82.00 | Apr 2021 | −109.6% | Miss |
| ONCBeiGene, Ltd. | Buy | $184.00 | Apr 2020 | +72.1% | Hit |
| ONCBeiGene, Ltd. | Buy | $200.00 | Mar 2018 | −32.1% | Hit |
| ONCBeiGene, Ltd. | Buy | $95.00 | Oct 2017 | +13.2% | Hit |
Matthew Harrison: analyst track record FAQ
Is Matthew Harrison a good stock analyst?
Yes, by track record. Matthew Harrison ranks number 203 of 347 of the analysts Bullish Whales scores, with a BW Score of 23 out of 100. Past results do not guarantee future ones.
What is Matthew Harrison's win rate?
Matthew Harrison's win rate is 45%. Across 35 scored calls, their rated stocks beat their sector 45% of the time over the next 12 months. On a typical call they returned −9.0% more than the sector.
What stocks and sectors does Matthew Harrison cover?
Matthew Harrison covers 9 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.
Are Matthew Harrison's price targets accurate?
Matthew Harrison's price targets are reached within 12 months 46% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.
How accurate are Wall Street analyst price targets?
Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.
Should I follow Matthew Harrison's stock ratings?
Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.
How does Bullish Whales score analyst accuracy?
Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.
How does Matthew Harrison rank among Wall Street analysts?
Matthew Harrison ranks number 203 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.